The Phaeo and Para Cancer Charity of the UK and ARJUNA Therapeutics Announce Their Collaboration

LONDON - May 23, 2023 - PRLog -- The Phaeo and Para Cancer Charity of the UK and ARJUNA Therapeutics announce their collaboration to develop treatments for rare tumours driven by mutations in the SDH-B gene. Phaeochromocytoma and paraganglioma are rarely occurring, progressive tumours of the nervous system, often caused by mutations in the SDH-B gene, without any curative treatment.

Jo Williamson, Chairman of the Phaeo and Para Cancer Charity and Chief Patient Representative of Arjuna said, "This is an exciting development for us. ARJUNA's drug showed excellent efficacy in a pre-clinical model of SDH-B mutant paraganglionoma and we're delighted to help support ongoing preclinical development of this potential treatment to given hope to phaeo/para patients and their families as well as potentially other groups of cancer patients".

Ross Breckenridge PhD FRCP, CEO of ARJUNA Therapeutics said, "ARJUNA is very grateful for the support of the Phaeo and Para Charity in this potential indication for our lead drug Ag5. Paraganglionoma/phaeochromocytoma driven by SDH-B mutation is a rare condition with no effective treatment but SDH-B mutation driven cancer in general is actually relatively frequent. We see this as a validation of our approach to targeting tumours with abnormal mitochondrial metabolism, an opportunity to address a clear unmet need that would benefit the quality of life of cancer patients, and a potentially extremely valuable market opportunity for Ag5".

The Phaeo and Para Cancer Charity of the UK was founded to research and develop treatments for this group of rare cancers.

ARJUNA Therapeutics is developing an entirely novel platform of small molecules that cross the blood-brain-barrier to address the unmet needs in cancer medicine. The first molecule in ARJUNA's pipeline is Ag5, a pan-tumour targeted therapy directed at tumours with mitochondrial dysfunction-a group that contains KRAS mutation driven cancers, glioblastoma multiforme as well as cancers driven by mutations in SDH-B.

More information about the company can be found at http://www.arjunatherapeutics.com